DarDoc Research

GLP-1 Trial & Approval Tracker

Compare GLP-1 trial arms

Compare results within a trial or inspect the context behind results from different studies.

ATTAIN-1

Foundayo

Without diabetes · 72 weeks · n=3,127

Double-blind, placebo-controlled. Treatment-regimen analysis. The trial used capsules with different strengths from the marketed tablets.

Mean body weight change at 72 weeks
  • Orforglipron 6 mg−7.5%
  • Orforglipron 12 mg−8.4%
  • Orforglipron 36 mg−11.2%
  • Placebo−2.1%
Published paper PubMed abstract NCT05869903

A direct comparison uses arms from the same trial. Switch to Two studies to inspect the context behind separate results.